Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

317 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer.
Fattori S, Le Roy A, Houacine J, Robert L, Abes R, Gorvel L, Granjeaud S, Rouvière MS, Ben Amara A, Boucherit N, Tarpin C, Pakradouni J, Charafe-Jauffret E, Houvenaeghel G, Lambaudie E, Bertucci F, Rochigneux P, Gonçalves A, Foussat A, Chrétien AS, Olive D. Fattori S, et al. Among authors: houvenaeghel g. Cancer Res. 2023 Sep 15;83(18):3026-3044. doi: 10.1158/0008-5472.CAN-23-0613. Cancer Res. 2023. PMID: 37379438 Free PMC article.
Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy.
Viens P, Jacquemier J, Bardou VJ, Bertucci F, Penault-Llorca F, Puig B, Gravis G, Oziel-Taïeb S, Resbeut M, Houvenaeghel G, Camerlo J, Birbaum D, Hassoun J, Maraninchi D. Viens P, et al. Among authors: houvenaeghel g. Breast Cancer Res Treat. 1999 Apr;54(3):205-12. doi: 10.1023/a:1006112927565. Breast Cancer Res Treat. 1999. PMID: 10445419
Prognosis of breast-carcinoma lymphagenesis evaluated by immunohistochemical investigation of vascular-endothelial-growth-factor receptor 3.
Jacquemier J, Mathoulin-Portier MP, Valtola R, Charafe-Jauffret E, Geneix J, Houvenaeghel G, Puig B, Bardou VJ, Hassoun J, Viens P, Birnbaum D. Jacquemier J, et al. Among authors: houvenaeghel g. Int J Cancer. 2000 Jan 20;89(1):69-73. doi: 10.1002/(sici)1097-0215(20000120)89:1<69::aid-ijc11>3.0.co;2-m. Int J Cancer. 2000. PMID: 10719733 Free article.
Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy.
Viret F, Chabannon C, Sainty D, Genre D, Gonçalves A, Arnoulet C, Gravis G, Bertucci F, Houvenaeghel G, Jacquemier J, Bardou VJ, Ladaique P, Braud AC, Maraninchi D, Viens P. Viret F, et al. Among authors: houvenaeghel g. Bone Marrow Transplant. 2003 Dec;32(11):1059-64. doi: 10.1038/sj.bmt.1704283. Bone Marrow Transplant. 2003. PMID: 14625576 Clinical Trial.
Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment.
Bertucci F, Tarpin C, Charafe-Jauffret E, Bardou VJ, Braud AC, Tallet A, Gravis G, Viret F, Gonçalves A, Houvenaeghel G, Blaise D, Jacquemier J, Maraninchi D, Viens P. Bertucci F, et al. Among authors: houvenaeghel g. Bone Marrow Transplant. 2004 May;33(9):913-20. doi: 10.1038/sj.bmt.1704458. Bone Marrow Transplant. 2004. PMID: 15004544
Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy.
Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Nguyen C, Maraninchi D, Jacquemier J, Houlgatte R, Birnbaum D, Viens P. Bertucci F, et al. Among authors: houvenaeghel g. Cancer Res. 2004 Dec 1;64(23):8558-65. doi: 10.1158/0008-5472.CAN-04-2696. Cancer Res. 2004. PMID: 15574762
317 results